NCT02419417: Study of BMS-986158 in Subjects With Select Advanced Cancers (BET)

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: BET
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 12 Years and older (Child, Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have a tumor that expresses BET
Exclusions: Patients who had prior treatment with a BET inhibitor

Comments are closed.

Up ↑